These factors could explain why AVL/HIV-AIDS patients already had CD4 cell counts lower than 200 cells/mm3 at the beginning of anti-leishmanial therapy (data not shown), which additionally could contribute to the maintenance of low levels during remission phase. The gene discussed is CD4; the disease is AIDS.